Industry

Meets the Growing Need for US-Based API Solubility and Bioavailability Enhancement Services QUAKERTOWN, Pa.–(BUSINESS WIRE)–Microsize today announced the launch of its business as an independent company to support solubility and bioavailability enhancement via particle reduction technologies including micronization. This announcement marks the completion of the previously announced intent to acquire the North American micronization business … [Read more…]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the company has joined an initiative created by the Department of Health and Human Services (HHS), in partnership with the White House, to address climate action through the reduction of greenhouse gas emissions. Earlier this week at the White … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “APAC Clinical Diagnostics Market 2021-2031” report has been added to ResearchAndMarkets.com’s offering. Asia Pacific clinical diagnostics market will grow by 9.8% annually with a total addressable market cap of $257.46 billion over 2022-2031, driven by the rising patient awareness and rising demand for high-quality care, growing healthcare spend, technological advancement, benefits of clinical … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Direct-acting Antiviral Drug Market Research Report by Type (NS3/4A Protease, NS5A Protein, and NS5B RNA-Dependent RNA polymerase), Indication, Route, Distribution Channel, State – United States Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering. The United States Direct-acting Antiviral Drug Market size was estimated at USD 1,676.39 … [Read more…]

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–IgGenix, Inc., a biotechnology company taking a revolutionary approach to directly alleviate allergic disease, today announced insights from its novel SeqSifter™ single-cell RNA-sequencing discovery platform demonstrating the potential for IgE antibody re-engineering in tree nut allergy. These data will be presented during the 2022 European Academy of Allergy and Clinical Immunology … [Read more…]

HIMALAYA Phase III trial subgroup analysis showed that IMFINZI plus tremelimumab improved overall survival vs. sorafenib in patients with unresectable liver cancer regardless of baseline liver functional reserve TOPAZ-1 Phase III trial subgroup analysis showed the addition of IMFINZI to standard-of-care chemotherapy improved overall survival benefit in patients with advanced biliary tract cancer regardless of … [Read more…]

TEL AVIV, Israel–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today the appointment of Eric A. Hughes, MD, PhD as Executive Vice President, Global R&D and Chief Medical Officer. Dr. Hughes will begin his employment on August 1, 2022, and will be based out of Teva’s U.S. headquarters in Parsippany, NJ. Dr. Hughes … [Read more…]

Hologic Taking Action with ‘Hey, U!’ Campaign to Educate Women in Conjunction with Fibroid Awareness Month MARLBOROUGH, Mass.–(BUSINESS WIRE)–#Fibroidawarenessmonth–A new survey commissioned by Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, revealed a lack of awareness among U.S. women about uterine health, including uterine fibroid symptoms and treatment options. Today, in conjunction with … [Read more…]

ST. HELIER, Jersey–(BUSINESS WIRE)–$NVCR–Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2022 on Thursday, July 28, 2022, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss the company’s financial results for the three and six months ended June 30, 2022, … [Read more…]

SUWON, South Korea–(BUSINESS WIRE)–#AMD—OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced the submission of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) to evaluate the safety and tolerability of OLX10212 for the treatment of advanced age-related macular degeneration (AMD). The objective of this Phase … [Read more…]